Dissolution enhancement of efavirenz by solid dispersion and PEGylation techniques

BACKGROUND: Efavirenz is the preferred nonnucleotide reverse transcriptase inhibitor for first-line antiretroviral treatment in many countries. It is orally active and is specific for human immunodeficiency virus type 1. Its effectiveness can be attributed to its long half-life, which is 52–76 h aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhavi, B. Bindu, Kusum, B., Chatanya, CH. Krishna, Madhu, M. Naga, Harsha, V. Sri, Banji, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2011
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465113/
https://www.ncbi.nlm.nih.gov/pubmed/23071917
http://dx.doi.org/10.4103/2230-973X.76726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465113/
https://www.ncbi.nlm.nih.gov/pubmed/23071917
http://dx.doi.org/10.4103/2230-973X.76726

Ejemplares similares